MMMT
MCID: CRC021
MIFTS: 65

Carcinosarcoma (MMMT)

Categories: Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Carcinosarcoma

MalaCards integrated aliases for Carcinosarcoma:

Name: Carcinosarcoma 11 19 53 43 14 71 75
Mixed Tumor, Mullerian 19 43 71
Malignant Mixed Mesodermal Tumor 11 71
Malignant Mixed Mullerian Tumor 11 19
Mixed Tumor, Mesodermal 43 16
Mmmt 11 19
Mixed Tumor, Not Otherwise Specified 71
Malignant Mixed Müllerian Tumor 75
Mixed Mesodermal Tumor 11
Mesodermal Mixed Tumor 11
Mullerian Mixed Tumor 11
Mixed Mullerian Tumor 19
Mixed Müllerian Tumor 75
Mixed Tumor Mullerian 53

Classifications:



External Ids:

Disease Ontology 11 DOID:4236
UMLS 71 C0007140 C0206627 C1334603 more

Summaries for Carcinosarcoma

GARD: 19 Malignant mixed Mullerian tumor (MMMT), also called a carcinosarcoma, is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary: Carcinosarcoma, also known as mixed tumor, mullerian, is related to fallopian tube carcinosarcoma and cervical carcinosarcoma. An important gene associated with Carcinosarcoma is VIM (Vimentin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Coenzyme M and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and cervix, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Disease Ontology: 11 A mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Wikipedia 75 Carcinosarcoma: Carcinosarcomas are malignant tumors that consist of a mixture of carcinoma (or epithelial cancer) and... more...

Malignant mixed müllerian tumor: A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor (MMMT) is a cancer... more...

Related Diseases for Carcinosarcoma

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 965)
# Related Disease Score Top Affiliating Genes
1 fallopian tube carcinosarcoma 32.2 WT1 TP53 CALB2
2 cervical carcinosarcoma 32.2 MME CALB2
3 ovarian carcinosarcoma 32.0 WT1 TP53 PIK3CA KRAS HRAS ERBB2
4 ovarian mesodermal adenosarcoma 31.8 WT1 KRT7
5 cervical adenosarcoma 31.4 WT1 TP53 PGR MME
6 chondrosarcoma 31.4 VIM S100A1 MUC1 DES
7 adenosarcoma 31.3 VIM TP53 PGR MME KIT ERBB2
8 blastoma 31.3 TP53 KRT7 KRAS KIT HRAS EGFR
9 lung sarcomatoid carcinoma 31.3 KRT7 KRAS HRAS EGFR CALB2
10 uterine carcinosarcoma 31.1 VIM TP53 PTEN PIK3CA KRAS KIT
11 uterine sarcoma 30.9 MME KIT DES
12 vaginal carcinosarcoma 30.8 TP53 PIK3CA MME KRT7 KRAS HRAS
13 fibrosarcoma 30.8 VIM TP53 KIT EGFR DES ACTC1
14 spindle cell sarcoma 30.8 VIM TP53 MUC1 KRT7 KIT DES
15 transitional cell carcinoma 30.7 TP53 PTEN KRT7 ERBB2 EGFR
16 pleomorphic adenoma 30.7 VIM TP53 S100A1 MUC1 ERBB2 DES
17 fibrous histiocytoma 30.7 VIM MME DES ACTC1
18 bizarre leiomyoma 30.6 TP53 PGR KIT
19 endometriosis 30.6 TP53 PTEN PGR CALB2
20 bladder adenocarcinoma 30.6 TP53 KRT7 CTNNB1
21 endodermal sinus tumor 30.6 VIM KRT7 KIT
22 malignant fibrous histiocytoma 30.6 VIM TP53 S100A1 MUC1 KIT DES
23 small cell carcinoma 30.6 TP53 PTEN KRT7 EGFR
24 cutaneous fibrous histiocytoma 30.6 S100A1 MME DES ACTC1
25 basaloid squamous cell carcinoma 30.6 TP53 KRT7 KIT
26 cholecystitis 30.5 TP53 MUC1 EGFR
27 benign teratoma 30.5 TP53 KRT7 CALB2
28 atypical polypoid adenomyoma 30.5 MME CTNNB1
29 mesenchymal cell neoplasm 30.5 TP53 MME KIT CTNNB1
30 neuroendocrine carcinoma 30.5 PTEN PGR MUC1 KRT7 KIT
31 malignant teratoma 30.5 WT1 TP53 KIT
32 malignant spiradenoma 30.5 TP53 KRT7
33 bilateral breast cancer 30.5 TP53 PTEN PGR ERBB2
34 leiomyosarcoma 30.5 WT1 VIM TP53 S100A1 PGR MUC1
35 uterus leiomyosarcoma 30.4 PGR KIT DES ACTC1
36 krukenberg carcinoma 30.4 KRT7 CALB2
37 lung benign neoplasm 30.4 TP53 KRT7 KRAS HRAS EGFR
38 keratoacanthoma 30.4 TP53 PIK3CA EGFR CTNNB1
39 tubular adenocarcinoma 30.3 PGR MUC1 MME KRT7 ERBB2 CTNNB1
40 cystic teratoma 30.3 TP53 MUC1 KRT7 CALB2
41 inguinal hernia 30.3 WT1 KIT CALB2
42 appendix adenocarcinoma 30.3 TP53 KRT7 KRAS HRAS
43 skin benign neoplasm 30.3 TP53 KRT7 HRAS
44 breast metaplastic carcinoma 30.3 TP53 PGR MME KRT7 ERBB2
45 clear cell adenocarcinoma 30.3 TP53 MME KRT7
46 gallbladder adenocarcinoma 30.2 TP53 MUC1 KRT7 HRAS ERBB2
47 bronchus cancer 30.2 KRT7 ERBB2 EGFR
48 adenomyoma 30.2 PGR MUC1 MME KRT7 CTNNB1
49 benign mesothelioma 30.2 WT1 KRT7 CALB2
50 basal cell carcinoma 30.2 TP53 PTEN MUC1 MME KRT7 EGFR

Graphical network of the top 20 diseases related to Carcinosarcoma:



Diseases related to Carcinosarcoma

Symptoms & Phenotypes for Carcinosarcoma

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

25 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.81 EGFR HRAS KRAS PIK3CA MUC1
2 Decreased viability GR00055-A-2 10.81 EGFR HRAS KRAS PIK3CA MUC1
3 Decreased viability GR00055-A-3 10.81 KRAS
4 Decreased viability GR00106-A-0 10.81 KRAS
5 Decreased viability GR00221-A-1 10.81 EGFR HRAS KIT KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.81 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.81 HRAS
8 Decreased viability GR00221-A-4 10.81 EGFR PIK3CA
9 Decreased viability GR00249-S 10.81 MUC1
10 Decreased viability GR00301-A 10.81 KIT KRAS
11 Decreased viability GR00381-A-1 10.81 KRAS
12 Decreased viability GR00402-S-2 10.81 PIK3CA
13 no effect GR00402-S-1 10.19 ACTC1 CALB2 CTNNB1 DES EGFR ERBB2
14 no effect GR00402-S-2 10.19 ACTC1 CALB2 CTNNB1 DES EGFR ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.97 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.97 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.97 FBXW7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.97 FBXW7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.97 VIM
20 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.97 FBXW7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.97 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.97 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.97 CTNNB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.97 FBXW7
25 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.97 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.97 KRAS VIM
27 Increased cell migration GR00055-A-1 9.67 CTNNB1
28 Increased cell migration GR00055-A-3 9.67 CTNNB1
29 Increased cell death in HCT116 cells GR00103-A-0 9.5 CTNNB1 FBXW7 PIK3CA
30 Reduced mammosphere formation GR00396-S 9.5 DES EGFR HRAS KRAS KRT7 PTEN
31 Decreased viability in pancreas lineage GR00235-A 9.43 KRT7 PGR TP53

MGI Mouse Phenotypes related to Carcinosarcoma:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.53 ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
2 normal MP:0002873 10.51 ACTC1 CALB2 CTNNB1 EGFR ERBB2 FBXW7
3 muscle MP:0005369 10.45 ACTC1 CTNNB1 DES EGFR ERBB2 HRAS
4 nervous system MP:0003631 10.44 ACTC1 CALB2 CTNNB1 EGFR ERBB2 FBXW7
5 neoplasm MP:0002006 10.42 CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
6 cellular MP:0005384 10.41 ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
7 cardiovascular system MP:0005385 10.36 ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
8 endocrine/exocrine gland MP:0005379 10.35 CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
9 behavior/neurological MP:0005386 10.31 ACTC1 CALB2 CTNNB1 DES ERBB2 HRAS
10 no phenotypic analysis MP:0003012 10.3 CTNNB1 EGFR HRAS KIT KRAS MUC1
11 embryo MP:0005380 10.3 CTNNB1 EGFR ERBB2 FBXW7 KIT KRAS
12 liver/biliary system MP:0005370 10.27 CTNNB1 EGFR FBXW7 KIT KRAS MME
13 digestive/alimentary MP:0005381 10.25 CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
14 renal/urinary system MP:0005367 10.24 CTNNB1 EGFR HRAS KIT KRAS KRT7
15 immune system MP:0005387 10.18 CTNNB1 EGFR FBXW7 KIT KRAS MME
16 limbs/digits/tail MP:0005371 10.16 CTNNB1 EGFR ERBB2 KIT KRAS PGR
17 respiratory system MP:0005388 10.15 CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
18 craniofacial MP:0005382 10.1 CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
19 reproductive system MP:0005389 10.1 CTNNB1 EGFR ERBB2 FBXW7 KIT KRAS
20 pigmentation MP:0001186 10.09 CTNNB1 EGFR KIT KRAS PTEN TP53
21 skeleton MP:0005390 9.96 CTNNB1 EGFR ERBB2 HRAS KIT KRAS
22 vision/eye MP:0005391 9.85 CTNNB1 EGFR FBXW7 KIT KRAS MUC1
23 mortality/aging MP:0010768 9.83 ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
24 integument MP:0010771 9.44 CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT

Drugs & Therapeutics for Carcinosarcoma

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Coenzyme M Approved, Investigational Phase 3 3375-50-6 598 23662354
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
4
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
5
Pertuzumab Approved Phase 2, Phase 3 380610-27-5
6
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Ifosfamide Approved Phase 3 3778-73-2 3690
9
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
10
Palifosfamide Investigational Phase 3 31645-39-3 100427
11 Liposomal doxorubicin Phase 2, Phase 3
12 Alkylating Agents Phase 3
13 Antineoplastic Agents, Alkylating Phase 3
14
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
15
Aflibercept Approved Phase 2 862111-32-8 124490314
16
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
17
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
18
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
19
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
20
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
21
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
22
Iodine Approved, Investigational Phase 2 7553-56-2 807
23
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
24
Fulvestrant Approved, Investigational Phase 1, Phase 2 129453-61-8 17756771 104741
25
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
26
Aldesleukin Approved Phase 2 110942-02-4
27
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
28
Olaparib Approved Phase 2 763113-22-0 23725625
29
Durvalumab Approved, Investigational Phase 2 1428935-60-7
30
Tremelimumab Approved, Investigational Phase 2 745013-59-6
31
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
32
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
33
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
34
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
35
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
36
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
37
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
38
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
39
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
40
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
41
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
42
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
43
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
44
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
45
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
47
Iniparib Investigational Phase 2 160003-66-7 9796068
48
Saracatinib Investigational Phase 2 379231-04-6 10302451
49
Rivoceranib Investigational Phase 2 811803-05-1 11315474
50
Exatecan Investigational Phase 1, Phase 2 171335-80-1 18546929 151115

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
2 A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
3 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
4 A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Recruiting NCT05256225 Phase 2, Phase 3 Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
5 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
6 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
7 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
8 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
9 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
10 Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) Completed NCT02993705 Phase 2 Trabectedin
11 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
12 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
13 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
14 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
15 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
16 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
17 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
18 A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma Completed NCT03395080 Phase 2 Paclitaxel;300mg DKN-01;600mg DKN-01
19 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
20 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
21 Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
22 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
23 Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
24 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
25 A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
26 A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
27 A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
28 A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
29 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
30 A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas Recruiting NCT05147558 Phase 2 Pembrolizumab;Lenvatinib
31 A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma Recruiting NCT05265793 Phase 2 Camrelizumab Combined With Apatinib
32 A Phase II Trial of Nivolumab for Recurrent/Metastatic Carcinosarcoma Recruiting NCT05224999 Phase 2 nivolumab
33 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
34 A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers Recruiting NCT05156268 Phase 2 Pembrolizumab;Olaparib
35 A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors Recruiting NCT05252416 Phase 1, Phase 2 BLU-222;Carboplatin;Ribociclib;Fulvestrant
36 Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors Recruiting NCT05001282 Phase 1, Phase 2 ELU001
37 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Recruiting NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
38 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine
39 A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2) Recruiting NCT04513665 Phase 2 ZW25
40 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
41 A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma Active, not recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
42 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Active, not recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
43 A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
44 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
45 An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma Active, not recruiting NCT03694262 Phase 2 Rucaparib;Bevacizumab;Atezolizumab
46 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Active, not recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
47 A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy. Active, not recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
48 Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Active, not recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
49 Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff Active, not recruiting NCT04802876 Phase 2 Spartalizumab
50 Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer Active, not recruiting NCT03241745 Phase 2 Nivolumab

Search NIH Clinical Center for Carcinosarcoma

Cochrane evidence based reviews: carcinosarcoma

Genetic Tests for Carcinosarcoma

Anatomical Context for Carcinosarcoma

Organs/tissues related to Carcinosarcoma:

MalaCards : Uterus, Smooth Muscle, Cervix, Skeletal Muscle, Colon, Pancreas, Bone

Publications for Carcinosarcoma

Articles related to Carcinosarcoma:

(show top 50) (show all 4591)
# Title Authors PMID Year
1
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. 53 62
20189232 2010
2
Intraductal carcinosarcoma with a heterologous mesenchymal component originating in intraductal papillary-mucinous carcinoma (IPMC) of the pancreas with both carcinoma and osteosarcoma cells arising from IPMC cells. 53 62
20203229 2010
3
Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. 53 62
19200930 2009
4
Carcinosarcoma of the gallbladder producing alpha-fetoprotein and manifesting as leukocytosis with elevated serum granulocyte colony-stimulating factor: report of a case. 53 62
19280285 2009
5
Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. 53 62
16648864 2006
6
Carcinosarcoma of the liver producing granulocyte-colony stimulating factor. 53 62
16792552 2006
7
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. 53 62
16157366 2006
8
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. 53 62
16140564 2006
9
Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. 53 62
15950966 2005
10
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. 53 62
15894930 2005
11
Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases. 53 62
15863125 2005
12
HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. 53 62
15901136 2005
13
ERBB-2 gene overexpression and amplification in uterine sarcomas. 53 62
15581967 2004
14
Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. 53 62
15223963 2004
15
Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. 53 62
12604887 2003
16
Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study. 53 62
12218209 2002
17
Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. 53 62
11687977 2001
18
Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. 53 62
11180164 2001
19
Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation. 53 62
9786352 1998
20
Uterine angiosarcomas: a morphologic and immunohistochemical study of four cases. 53 62
9500227 1998
21
Carcinosarcoma of the prostate. A case report and a possible evidence on the role of hormonal therapy. 53 62
9313326 1997
22
Effects of staurosporine, K 252a and other structurally related protein kinase inhibitors on shape and locomotion of Walker carcinosarcoma cells. 53 62
1457347 1992
23
Immunohistochemical study of the histogenesis of esophageal carcinosarcoma. 53 62
1283991 1992
24
Thymic carcinosarcoma associated with a spindle cell thymoma: an immunohistochemical study. 53 62
1398523 1992
25
Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas. 53 62
1612579 1992
26
Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. 53 62
1672262 1991
27
Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature. 53 62
2201434 1990
28
An immunohistological comparison of primary lung carcinosarcoma and sarcoma. 53 62
1696005 1990
29
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. 62
36206301 2022
30
A look towards the clonal origin of metastatic pulmonary carcinosarcoma: Report of a patient with an unexpected long-term survival. 62
35168438 2022
31
Pelvic Carcinosarcoma Showing a Diverse Histology and Hierarchical Gene Mutation with a Common POLE Mutation to Endometrial Endometroid Carcinoma: A Case Report. 62
35360975 2022
32
Primary Cutaneous Carcinosarcoma Treated With Mohs Micrographic Surgery in a Hospice Patient. 62
36449880 2022
33
Improved survival with combination chemotherapy and external beam radiation therapy in uterine carcinosarcoma. 62
36343971 2022
34
Transanal total mesorectal excision for primary rectovaginal carcinosarcoma: A case report and literature review. 62
36369664 2022
35
Carcinosarcoma of the esophago-gastric junction-a case description. 62
36330176 2022
36
Morphological and Immunohistochemical Characterization of an Oral Metastatic Carcinosarcoma in a Cat. 62
36265216 2022
37
Sinonasal carcinosarcoma with cartilaginous and rhabdomyoblastic components: A previously undescribed entity. 62
35595621 2022
38
Merkel Cell Carcinosarcoma With a Bland Sarcomatous Component. 62
36075572 2022
39
Mesonephric-like Carcinosarcoma of the Uterine Corpus: Clinicopathological, Molecular and Prognostic Characteristics in Comparison With Uterine Mesonephric-like Adenocarcinoma and Conventional Endometrial Carcinosarcoma. 62
36316041 2022
40
Impact of lymph node staging in presumed early-stage ovarian carcinoma. 62
36108452 2022
41
Alternative Lengthening of Telomeres in Primary Hepatic Neoplasms. 62
36370823 2022
42
Small Cell and Other Rare Histologic Types of Cervical Cancer. 62
35947285 2022
43
Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events. 62
36470146 2022
44
Radical abdomino-pelvic surgery in the management of uterine carcinosarcoma with concomitant para-aortic lymphadenopathy metastasising from anal carcinoma. 62
36450419 2022
45
Carcinoma ex-pleomorphic adenoma of mandible: A case report and review of literature. 62
36274292 2022
46
Salivary carcinosarcoma: insight into multistep pathogenesis indicates uniform origin as sarcomatoid variant of carcinoma ex pleomorphic adenoma with frequent heterologous elements. 62
36376255 2022
47
Feline uterine carcinosarcoma infiltrated with osteoclast-like giant cells. 62
36261364 2022
48
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. 62
36243601 2022
49
Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature. 62
36186232 2022
50
Molecular and expressional characterization of tumor heterogeneity in pulmonary carcinosarcoma. 62
35848137 2022

Variations for Carcinosarcoma

Cosmic variations for Carcinosarcoma:

8 (show top 50) (show all 37170)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM142838165 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.797G>A p.G266E 17:7673823-7673823 5
2 COSM144013119 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.698G>A p.G233D 17:7674232-7674232 5
3 COSM122733885 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.335G>A p.G112D 17:7674232-7674232 5
4 COSM106054488 TP53 cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.797G>A p.G266E 17:7673823-7673823 5
5 COSM134704780 KRAS pancreas,NS,carcinoma,carcinosarcoma c.100C>T p.P34S 12:25245285-25245285 5
6 COSM91938726 KRAS pancreas,NS,carcinoma,carcinosarcoma c.100C>T p.P34S 12:25245285-25245285 5
7 COSM135063814 KRAS pancreas,NS,carcinoma,carcinosarcoma c.100C>T p.P34S 12:25245285-25245285 5
8 COSM87892689 KRAS pancreas,NS,carcinoma,carcinosarcoma c.100C>T p.P34S 12:25245285-25245285 5
9 COSM90140159 TRAF7 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.1732G>A p.E578K 16:2175939-2175939 4
10 COSM144158749 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.512T>A p.L171H 17:7673539-7673539 4
11 COSM144315379 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.287G>A p.C96Y 17:7675208-7675208 4
12 COSM111836164 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.423C>T p.C141= 17:7675189-7675189 4
13 COSM144651337 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 4
14 COSM142559914 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.407G>A p.R136H 17:7675088-7675088 4
15 COSM145019014 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.598A>G p.N200D 17:7674248-7674248 4
16 COSM122762842 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.94A>G p.K32E 17:7675122-7675122 4
17 COSM87900846 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.380C>T p.S127F 17:7675232-7675232 4
18 COSM121875541 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.422G>A p.R141H 17:7673802-7673802 4
19 COSM122734335 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.337G>A p.G113S 17:7674230-7674230 4
20 COSM87898527 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.814G>A p.V272M 17:7673806-7673806 4
21 COSM144658149 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.287G>A p.C96Y 17:7675208-7675208 4
22 COSM143944147 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.265C>T p.R89W 17:7674221-7674221 4
23 COSM144148837 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.-55C>T p.? 17:7675189-7675189 4
24 COSM143158810 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.-98C>T p.? 17:7675232-7675232 4
25 COSM105654789 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 4
26 COSM143943941 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.337G>A p.V113M 17:7673806-7673806 4
27 COSM143156843 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.266G>A p.R89Q 17:7674220-7674220 4
28 COSM87897711 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.818G>A p.R273H 17:7673802-7673802 4
29 COSM121876485 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.421C>T p.R141C 17:7673803-7673803 4
30 COSM142837497 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 4
31 COSM122299085 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.94A>G p.K32E 17:7675122-7675122 4
32 COSM121876255 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.315G>A p.M105I 17:7674252-7674252 4
33 COSM143370575 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.701G>A p.R234H 17:7673802-7673802 4
34 COSM111758775 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 4
35 COSM106053434 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.742C>T p.R248W 17:7674221-7674221 4
36 COSM112282360 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 4
37 COSM144087235 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.234G>A p.M78I 17:7674252-7674252 4
38 COSM143371076 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 4
39 COSM106080940 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 4
40 COSM106124583 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.423C>T p.C141= 17:7675189-7675189 4
41 COSM144015546 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.347C>T p.S116F 17:7675232-7675232 4
42 COSM142846805 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.725G>C p.C242S 17:7674238-7674238 4
43 COSM142560476 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 4
44 COSM121876163 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.418G>A p.V140M 17:7673806-7673806 4
45 COSM143372002 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.598A>G p.N200D 17:7674248-7674248 4
46 COSM144311239 TP53 lung,NS,carcinoma,carcinosarcoma c.680G>A p.G227E 17:7673823-7673823 4
47 COSM144091376 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.-74G>A p.? 17:7675208-7675208 4
48 COSM122277699 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.8G>A p.C3Y 17:7675208-7675208 4
49 COSM112327118 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.423C>T p.C141= 17:7675189-7675189 4
50 COSM145024439 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.287G>A p.C96Y 17:7675208-7675208 4

Expression for Carcinosarcoma

Search GEO for disease gene expression data for Carcinosarcoma.

Pathways for Carcinosarcoma

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 VIM TP53 S100A1 PTEN PIK3CA MUC1
2
Show member pathways
13.87 VIM TP53 PTEN MUC1 KRAS KIT
3
Show member pathways
13.83 TP53 S100A1 PTEN PIK3CA MUC1 KRAS
4 13.78 VIM TP53 PTEN PIK3CA PGR KRAS
5
Show member pathways
13.53 TP53 PTEN PIK3CA KRAS HRAS ERBB2
6
Show member pathways
13.46 TP53 PTEN KRAS KIT HRAS ERBB2
7
Show member pathways
13.42 PTEN PIK3CA KRAS KIT HRAS FBXW7
8
Show member pathways
13.35 PTEN KRAS KIT HRAS ERBB2 EGFR
9
Show member pathways
13.33 CTNNB1 EGFR ERBB2 HRAS KIT KRAS
10
Show member pathways
13.12 TP53 PTEN PIK3CA KIT ERBB2 EGFR
11
Show member pathways
13.12 TP53 PTEN KRAS KIT HRAS EGFR
12
Show member pathways
13.01 TP53 PTEN PIK3CA KRAS KIT HRAS
13
Show member pathways
12.93 PTEN PIK3CA KRAS HRAS ERBB2 EGFR
14
Show member pathways
12.89 PIK3CA MME KRAS HRAS CTNNB1
15
Show member pathways
12.89 PIK3CA KRAS KIT HRAS EGFR
16 12.89 CTNNB1 EGFR ERBB2 HRAS KIT KRAS
17
Show member pathways
12.83 KRAS HRAS EGFR DES CTNNB1
18
Show member pathways
12.74 PTEN PIK3CA KIT ERBB2 EGFR
19 12.71 TP53 PTEN PIK3CA KIT HRAS EGFR
20
Show member pathways
12.7 EGFR HRAS KIT KRAS PIK3CA TP53
21
Show member pathways
12.65 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
22
Show member pathways
12.64 TP53 PTEN PIK3CA KRAS KIT HRAS
23 12.6 VIM MUC1 KRT7 DES ACTC1
24
Show member pathways
12.53 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
25
Show member pathways
12.47 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
26
Show member pathways
12.46 EGFR HRAS KRAS PIK3CA
27 12.46 TP53 KRAS HRAS EGFR
28
Show member pathways
12.45 PIK3CA KRAS HRAS CTNNB1
29
Show member pathways
12.43 CTNNB1 EGFR ERBB2 HRAS KIT KRAS
30
Show member pathways
12.38 PIK3CA HRAS ERBB2 EGFR
31
Show member pathways
12.37 PTEN PIK3CA KRAS HRAS
32
Show member pathways
12.37 PIK3CA KRAS HRAS CTNNB1
33 12.36 PTEN PIK3CA HRAS ERBB2 EGFR CTNNB1
34
Show member pathways
12.34 CTNNB1 EGFR ERBB2 HRAS KRAS MUC1
35
Show member pathways
12.32 TP53 PTEN PIK3CA HRAS
36 12.32 EGFR HRAS KIT KRAS PIK3CA
37
Show member pathways
12.31 PIK3CA KRAS HRAS ERBB2 EGFR
38
Show member pathways
12.3 PIK3CA HRAS EGFR CTNNB1
39
Show member pathways
12.27 PTEN KRAS HRAS EGFR
40
Show member pathways
12.27 EGFR ERBB2 HRAS KRAS PIK3CA PTEN
41 12.25 TP53 KRAS EGFR CTNNB1
42 12.25 TP53 PIK3CA KRAS HRAS CTNNB1
43
Show member pathways
12.21 KRAS HRAS ERBB2 EGFR
44 12.21 CTNNB1 EGFR KRAS PTEN TP53
45
Show member pathways
12.2 TP53 PTEN PIK3CA HRAS
46
Show member pathways
12.19 PTEN PIK3CA HRAS ERBB2 EGFR CTNNB1
47 12.17 TP53 PTEN KRAS ERBB2 EGFR
48
Show member pathways
12.16 PIK3CA KRAS HRAS EGFR
49
Show member pathways
12.12 PIK3CA PGR KRAS HRAS ERBB2 EGFR
50
Show member pathways
12.11 PIK3CA KRAS HRAS ERBB2 EGFR

GO Terms for Carcinosarcoma

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.85 ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
2 focal adhesion GO:0005925 9.73 VIM MME KRAS EGFR CTNNB1 ACTC1

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.15 PTEN KRAS KIT HRAS ERBB2 EGFR
2 negative regulation of apoptotic process GO:0043066 10.13 ACTC1 CTNNB1 EGFR ERBB2 PTEN TP53
3 MAPK cascade GO:0000165 10.1 KRAS HRAS EGFR CTNNB1
4 heart development GO:0007507 10.06 WT1 TP53 PTEN ERBB2 CTNNB1
5 positive regulation of MAP kinase activity GO:0043406 10.01 KIT HRAS ERBB2 EGFR
6 negative regulation of gene expression GO:0010629 10 TP53 PIK3CA PGR HRAS FBXW7 CTNNB1
7 phosphatidylinositol 3-kinase signaling GO:0014065 9.95 PTEN PIK3CA ERBB2
8 vasculature development GO:0001944 9.83 CTNNB1 FBXW7 PIK3CA
9 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.81 TP53 MUC1
10 cell population proliferation GO:0008283 9.63 TP53 PTEN KRAS KIT EGFR CTNNB1
11 regulation of cell population proliferation GO:0042127 9.56 CTNNB1 EGFR ERBB2 HRAS KIT TP53
12 positive regulation of gene expression GO:0010628 9.53 WT1 VIM TP53 PGR KRAS KIT

Molecular functions related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.93 VIM TP53 S100A1 PTEN PGR KRAS
2 protein phosphatase binding GO:0019903 9.23 TP53 ERBB2 EGFR CTNNB1

Sources for Carcinosarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....